ArticleEuropean journal of immunology2026
Growing up as an Immunologist Among Molecular Geneticists.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When I started my independent career as a young medical doctor at the Institute for Genetics in Cologne in 1964, among a faculty of enthusiastic young scientists devoted to the then new field of molecular genetics, my hope to address the basic mysteries of immunology at a similar level was entirely speculative. But the situation changed dramatically over the next three decades, during which we witnessed, and contributed to, the incorporation of basic methods of bacterial and bacteriophage genetics into immunological research, including mutational analysis, ultimately developed into conditional targeted mutagenesis in the mouse. This was accompanied by revolutionary advances in cell separation, the advent of monoclonal antibodies, as well as nucleic acid amplification and sequencing technologies. The present article describes some of the activities of my group in Cologne over these times, focusing on how things got underway in this unique historical context, and along the lines of a lecture given in acceptance of the inaugural EFIS Lifetime Achievement Award in Vienna, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.